Stock RAPT RAPT THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
8.1 USD +3.85% Intraday chart for RAPT Therapeutics, Inc. +1.89% -67.40%
Apr. 09 RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients CI
Mar. 27 JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating MT

Business Summary

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.

Number of employees: 131

Managers

Managers TitleAgeSince
Brian Wong CEO
 Chief Executive Officer 52 15-07-31
Rodney Young DFI
 Director of Finance/CFO 61 19-12-01
Jim Farmer CTO
 Chief Tech/Sci/R&D Officer - 22-05-03
William Ho CTO
 Chief Tech/Sci/R&D Officer 58 15-04-30
Dirk Brockstedt CTO
 Chief Tech/Sci/R&D Officer 55 17-12-31
Nipun Davar CTO
 Chief Tech/Sci/R&D Officer - Feb. 12
Sylvia R. Wheeler IRC
 Investor Relations Contact 63 -
Michael Listgarten LAW
 General Counsel - 23-05-02
Adnan Rahman PRN
 Corporate Officer/Principal - 22-09-27
Shari L. Geffon PRN
 Corporate Officer/Principal - 22-05-03

Members of the board

Members of the board TitleAgeSince
Mary Gray BRD
 Director/Board Member 71 19-12-03
William Rieflin CHM
 Chairman 64 15-04-30
Wendye Robbins BRD
 Director/Board Member 63 19-10-21
Brian Wong CEO
 Chief Executive Officer 52 15-07-31
Michael Giordano BRD
 Director/Board Member 66 17-12-31
Linda Kozick BRD
 Director/Board Member 66 16-11-30
Lori Lyons-Williams BRD
 Director/Board Member 46 21-11-08

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 34,799,702 32,017,440 ( 92.00 %) 0 92.00 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
11.04 %
3,843,387 11.04 % 35 M $
Redmile Group LLC
10.85 %
3,776,847 10.85 % 34 M $
T. Rowe Price International Ltd.
9.810 %
3,413,552 9.810 % 31 M $
The Column Group LLC
7.703 %
2,680,621 7.703 % 24 M $
BlackRock Advisors LLC
6.695 %
2,329,567 6.695 % 21 M $
Perceptive Advisors LLC
6.150 %
2,139,950 6.150 % 19 M $
Vanguard Fiduciary Trust Co.
5.909 %
2,056,221 5.909 % 18 M $
Deep Track Capital LP
5.155 %
1,793,966 5.155 % 16 M $
STATE STREET CORPORATION
4.180 %
1,454,556 4.180 % 13 M $
T. Rowe Price Investment Management, Inc.
3.672 %
1,277,861 3.672 % 11 M $

Company contact information

Rapt Therapeutics, Inc.

561 Eccles Avenue

94080, South San Francisco

+650 489 9000

http://rapt.com
address RAPT Therapeutics, Inc.(RAPT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
8.1 USD
Average target price
22 USD
Spread / Average Target
+171.60%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RAPT THERAPEUTICS, INC. Stock RAPT Therapeutics, Inc.
-67.40% 282M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RAPT Stock
  4. Company RAPT Therapeutics, Inc.